Literature DB >> 26984820

Lack of hippocampal CB1 receptor desensitization by Δ(9)-tetrahydrocannabinol in aged mice and by low doses of JZL 184.

Monika Feliszek1, Laura Bindila2, Beat Lutz2, Andreas Zimmer3, Andras Bilkei-Gorzo3, Eberhard Schlicker4.   

Abstract

Activation of cannabinoid CB1 receptors may offer new therapeutic strategies, but the efficiency of CB1 receptor agonists may be impaired by tolerance development upon prolonged administration. We compared the influence of repeated administration of Δ(9)-tetrahydrocannabinol (THC) 10 mg/kg on the motility and on basal and CB1 receptor-stimulated (35)S-GTPγS binding of adolescent and aged mice. Moreover, we determined the influence of JZL 184 (which inhibits the 2-arachidonoylglycerol, 2-AG, degrading enzyme monoacylglycerol lipase, MAGL) on (35)S-GTPγS binding and 2-AG levels of young adult mice. Mouse motility was tested in the open field. (35)S-GTPγS binding was studied in hippocampal membranes. THC and CP 55,940 were used as cannabinoid agonists in the behavioural and biochemical studies, respectively. 2-AG levels were quantified by liquid chromatography-multiple reaction monitoring. The THC (10 mg/kg)-induced hypomotility was stronger in untreated than in THC-pretreated adolescent mice but similar in both treatment groups of aged mice. Basal and stimulated (35)S-GTPγS binding was decreased in membranes from THC-pretreated adolescent but not affected in membranes from aged mice. Treatment of young adult mice with JZL 184 (4, 10 and 40 mg/kg) for 14 days did not affect basal binding. Stimulated binding tended to be decreased by 25 % only in mice treated with JZL 184 (40 mg/kg). Hippocampal 2-AG level was increased by JZL 184 at 40 and 10 but not affected at 4 mg/kg. In conclusion, CB1 receptor tolerance does not occur in aged mice pretreated with THC and in young adult mice treated with a low dose of the MAGL inhibitor JZL 184.

Entities:  

Keywords:  2-Arachidonoylglycerol (2-AG); 35S-GTPγS binding; Hippocampus; JZL 184; Open-field activity; Δ9-Tetrahydrocannabinol (THC)

Mesh:

Substances:

Year:  2016        PMID: 26984820     DOI: 10.1007/s00210-016-1226-6

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  59 in total

Review 1.  The endocannabinoid system and the brain.

Authors:  Raphael Mechoulam; Linda A Parker
Journal:  Annu Rev Psychol       Date:  2012-07-12       Impact factor: 24.137

2.  The monoacylglycerol lipase inhibitor JZL184 suppresses inflammatory pain in the mouse carrageenan model.

Authors:  Sudeshna Ghosh; Laura E Wise; Yugang Chen; Ramesh Gujjar; Anu Mahadevan; Benjamin F Cravatt; Aron H Lichtman
Journal:  Life Sci       Date:  2012-06-28       Impact factor: 5.037

3.  MAM-2201, a synthetic cannabinoid drug of abuse, suppresses the synaptic input to cerebellar Purkinje cells via activation of presynaptic CB1 receptors.

Authors:  Tomohiko Irie; Ruri Kikura-Hanajiri; Makoto Usami; Nahoko Uchiyama; Yukihiro Goda; Yuko Sekino
Journal:  Neuropharmacology       Date:  2015-03-05       Impact factor: 5.250

4.  Repeated low-dose administration of the monoacylglycerol lipase inhibitor JZL184 retains cannabinoid receptor type 1-mediated antinociceptive and gastroprotective effects.

Authors:  Steven G Kinsey; Laura E Wise; Divya Ramesh; Rehab Abdullah; Dana E Selley; Benjamin F Cravatt; Aron H Lichtman
Journal:  J Pharmacol Exp Ther       Date:  2013-02-14       Impact factor: 4.030

Review 5.  Effects of cannabinoids on neurotransmission.

Authors:  B Szabo; E Schlicker
Journal:  Handb Exp Pharmacol       Date:  2005

6.  Role of cannabinoid receptor type 1 desensitization in greater tetrahydrocannabinol impairment of memory in adolescent rats.

Authors:  Nicole L T Moore; Ashley L R Greenleaf; Shawn K Acheson; Wilkie A Wilson; H Scott Swartzwelder; Cynthia M Kuhn
Journal:  J Pharmacol Exp Ther       Date:  2010-07-28       Impact factor: 4.030

7.  Role of receptor internalization in the agonist-induced desensitization of cannabinoid type 1 receptors.

Authors:  Dai-Fei Wu; Li-Quan Yang; Andrea Goschke; Ralf Stumm; Lars-Ove Brandenburg; Ying-Jian Liang; Volker Höllt; Thomas Koch
Journal:  J Neurochem       Date:  2007-11-06       Impact factor: 5.372

Review 8.  Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids.

Authors:  Laura J Sim-Selley
Journal:  Crit Rev Neurobiol       Date:  2003

Review 9.  Chemical probes of endocannabinoid metabolism.

Authors:  Jacqueline L Blankman; Benjamin F Cravatt
Journal:  Pharmacol Rev       Date:  2013-03-19       Impact factor: 25.468

10.  Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects.

Authors:  Jonathan Z Long; Weiwei Li; Lamont Booker; James J Burston; Steven G Kinsey; Joel E Schlosburg; Franciso J Pavón; Antonia M Serrano; Dana E Selley; Loren H Parsons; Aron H Lichtman; Benjamin F Cravatt
Journal:  Nat Chem Biol       Date:  2008-11-23       Impact factor: 15.040

View more
  4 in total

Review 1.  The endocannabinoid system as a target for novel anxiolytic drugs.

Authors:  Sachin Patel; Mathew N Hill; Joseph F Cheer; Carsten T Wotjak; Andrew Holmes
Journal:  Neurosci Biobehav Rev       Date:  2017-05       Impact factor: 8.989

Review 2.  Cannabinoid Modulation of the Stressed Hippocampus.

Authors:  Franciele F Scarante; Carla Vila-Verde; Vinícius L Detoni; Nilson C Ferreira-Junior; Francisco S Guimarães; Alline C Campos
Journal:  Front Mol Neurosci       Date:  2017-12-19       Impact factor: 5.639

3.  Cannabinoid 1 receptor signaling on GABAergic neurons influences astrocytes in the ageing brain.

Authors:  Andras Bilkei-Gorzo; Onder Albayram; Frank Ativie; Safak Chasan; Till Zimmer; Karsten Bach; Andreas Zimmer
Journal:  PLoS One       Date:  2018-08-16       Impact factor: 3.240

4.  Neuroprotection of retinal ganglion cells in vivo using the activation of the endogenous cannabinoid signaling system in mammalian eyes.

Authors:  Greg Maguire; Christy Eubanks; George Ayoub
Journal:  Neuronal Signal       Date:  2022-02-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.